IPSEN, OOO
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- Ipsen
- Registration Number
- NCT00517491
- Locations
- 🇲🇽
Centro Médico Nacional Siglo XXI, IMSS, Mexico City, Mexico
Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
- Conditions
- Acromegaly
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 63
- Registration Number
- NCT00499993
- Locations
- 🇮🇹
Ospedale Maggiore, Bologna, Italy
🇮🇹Università deglis Studi di Cagliari, Cagliari, Italy
🇮🇹Azienda Ospedaliera "V. Cervello", Palermo, Italy
Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
- Conditions
- Acromegaly
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 55
- Registration Number
- NCT00500227
- Locations
- 🇪🇸
Hospital Prínceps d'Espanya, Barcelona, Spain
🇪🇸Hospital General de la Vall d´Hebron, Barcelona, Spain
🇪🇸Hospital "Mútua de Terrassa", Barcelona, Spain
Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease
- Conditions
- Alzheimer Disease
- Interventions
- Drug: EGb 761® (Tanakan®)
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 40
- Registration Number
- NCT00500500
- Locations
- 🇫🇷
Hôpital La Timone, Marseille, France
Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 117
- Registration Number
- NCT00489255
- Locations
- 🇺🇸
Neurological Institute, Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Parkinson's Disease and Movement Disorders Center of Long Island, Commack, New York, United States
🇺🇸Kingston Neurological Associates, Kingston, New York, United States
A Post Marketing Surveillance Program for NutropinAq® in Paediatric Growth Disorders
- Conditions
- Growth Hormone Disorders
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 3690
- Registration Number
- NCT00455728
- Locations
- 🇬🇧
Ipsen Central Contact, Slough, Berkshire, United Kingdom
A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone Deficiency
- Conditions
- Growth Hormone Disorders
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 546
- Registration Number
- NCT00455884
- Locations
- 🇬🇧
Ipsen Central Contact, Slough, Berkshire, United Kingdom
Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
- Conditions
- Cerebral Palsy
- Interventions
- Biological: Botulinum toxin type A
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 6
- Registration Number
- NCT00455637
- Locations
- 🇬🇧
Chailey Heritage Clinical Services, Chailey, United Kingdom
Study to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar Fasciitis
- Conditions
- Chronic Plantar Fasciitis
- Interventions
- Biological: Botulinum toxin type ADrug: Placebo
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 40
- Registration Number
- NCT00447876
- Locations
- 🇩🇪
University Hospital Charite, Campus Virchow, Musculoskeletal Centre, Orthopedic Clinic, Berlin, Germany
🇩🇪Orthopedic Practice Biberburg, Berlin, Germany
🇩🇪Klinik für Orthopädie und Rheumatologie, Universitätsklinikum Gießen und Marburg GmbH, Marburg, Germany
Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia
- Conditions
- Cervical Dystonia
- Interventions
- Biological: Botulinum toxin type A
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 516
- Registration Number
- NCT00447772
- Locations
- 🇩🇪
Städt. Krankenhaus Martha-Maria, Halle, Germany
🇩🇪Gemeinschaftspraxis für Neurologie/Psychiatrie, Lüneburg, Germany
🇩🇪Westpfalz-Klinikum GmbH, Kaiserslautern, Germany